InsidersTradesSigma
Track the Natures Sunshine Products INC share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Natures Sunshine Products INC has published 265 public disclosures. Market capitalisation: €250m. The latest transaction was reported on 3 September 2026 (Attribution). Among the most active insiders: Norman Daniel C. The full history is free.
265
Insider Decl.
n/a
Thresholds
€2m
20 ops.
Buy Volume
€30m
20 ops.
Sell Volume
40Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 2,021 of 29,062 companies
76.8
score / 100
Value83
Quality70
FCF yld12%
Earn yld7.8%
EV/EBITDA6.1x
ROE11%
Gross mgn72%
Net mgn4.1%
Debt/EBITDA0.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 3 September 2026
Declarations265 total
7,210 shares0Common SharesSEC:0001628280-26-060339:0
20,000 shares@ US$14.690.11% mcap11.2% of flowCommon Stock, no par valueSEC:0001166152-26-000011:0
Canonical exit: 15 Nov 2026 (T+90)
1,000 shares@ US$16.480.0057% mcap0.7% of flowCommon Stock, no par valueSEC:0001166152-26-000010:3
Canonical exit: 5 Nov 2026 (T+90)
20,000 shares@ US$16.690.12% mcap14.4% of flowCommon Stock, no par valueSEC:0001166152-26-000010:7
Canonical exit: 5 Nov 2026 (T+90)
10,000 shares@ US$16.720.058% mcap7.2% of flowCommon Stock, no par valueSEC:0001166152-26-000010:8
Canonical exit: 5 Nov 2026 (T+90)
876 shares@ US$15.640.0048% mcap0.6% of flowCommon Stock, no par valueSEC:0001166152-26-000010:9
Canonical exit: 8 Nov 2026 (T+90)
16,928 shares@ US$15.800.093% mcap11.5% of flowCommon Stock, no par valueSEC:0001166152-26-000010:10
Canonical exit: 8 Nov 2026 (T+90)
13,072 shares@ US$15.780.072% mcap8.9% of flowCommon Stock, no par valueSEC:0001166152-26-000010:11
Canonical exit: 8 Nov 2026 (T+90)
10,000 shares@ US$16.010.056% mcap6.9% of flowCommon Stock, no par valueSEC:0001166152-26-000010:12
Canonical exit: 8 Nov 2026 (T+90)
2,000 shares@ US$16.350.011% mcap1.4% of flowCommon Stock, no par valueSEC:0001166152-26-000010:0
Canonical exit: 4 Nov 2026 (T+90)
2,513 shares@ US$16.750.015% mcap1.8% of flowCommon Stock, no par valueSEC:0001166152-26-000010:1
Canonical exit: 4 Nov 2026 (T+90)
10,000 shares@ US$16.460.057% mcap7.1% of flowCommon Stock, no par valueSEC:0001166152-26-000010:2
Canonical exit: 5 Nov 2026 (T+90)
20,000 shares@ US$16.550.12% mcap14.3% of flowCommon Stock, no par valueSEC:0001166152-26-000010:4
Canonical exit: 5 Nov 2026 (T+90)
5,000 shares@ US$16.620.029% mcap3.6% of flowCommon Stock, no par valueSEC:0001166152-26-000010:5
Canonical exit: 5 Nov 2026 (T+90)
30,000 shares@ US$16.680.17% mcap21.6% of flowCommon Stock, no par valueSEC:0001166152-26-000010:6
Canonical exit: 5 Nov 2026 (T+90)
1,976 sharesCommon SharesSEC:0001628280-26-045913:0
12,015 shares@ US$21.840.10% mcap32.0% of flowCommon SharesSEC:0001628280-26-037603:0
3,512 shares@ US$27.070.037% mcap12.7% of flowCommon SharesSEC:0001628280-26-026367:0
1,289 shares@ US$27.070.013% mcap4.2% of flowCommon SharesSEC:0001628280-26-026369:0
951 shares@ US$27.070.0099% mcap9.0% of flowCommon SharesSEC:0001628280-26-026365:0
1,567 shares@ US$27.070.016% mcap6.2% of flowCommon SharesSEC:0001628280-26-026361:0
1,567 shares@ US$27.070.016% mcap7.5% of flowCommon SharesSEC:0001628280-26-026363:0
11,798 sharesCommon SharesSEC:0001628280-26-021359:0
7,965 sharesCommon SharesSEC:0001628280-26-021377:0
8,180 sharesCommon SharesSEC:0001628280-26-021375:0
25 of 265 declarations
关于 Natures Sunshine Products INC
Nature’s Sunshine Products, Inc. (Nasdaq: NATR) 是一家在美国纳斯达克市场上市的公司。公司总部位于犹他州莱希，是天然健康和保健领域的长期参与者，拥有超过50年的历史。其核心业务是配方、制造和销售草药补充剂、营养产品和精选个人护理用品，品牌定位以天然成分、产品质量和健康导向的日常习惯为中心。（[sec.gov](https://www.sec.gov/Archives/edgar/data/0000275053/000162828026016535/natrq42025earningsrelease.htm)） 从行业角度来看，Nature’s Sunshine 处于竞争激烈的中等市值消费者健康利基市场，品牌信任、成分采购、监管纪律和产品创新至关重要。公司强调其大部分产品通过自有设施生产，从而更好地控制质量、安全性和功效。它还在全球40多个国家分销产品，这提供了有意义的地理多元化，并减少了对单一市场的依赖。对于寻求具有全球影响力的美国健康业务的投资者来说，这种国际足迹尤其重要。（[sec.gov](https://www.sec.gov/Archives/edgar/data/0000275053/000162828026016535/natrq42025earningsrelease.htm)） 产品组合包括草药和营养补充剂、日常健康配方以及针对消化、活力、新陈代谢支持和一般健康维护的特定类别产品线。2025年，Nature’s Sunshine 重新推出了其 Power Line，并推出了新的 Power Balance 补充剂，这表明公司积极进行产品组合管理，并愿意根据消费者健康趋势更新其产品。公司还推出了其首个综合品牌平台“Be More Earth”，这强化了其天然定位，并强调了成分真实性在其营销策略中的作用。（[ir.naturessunshine.com](https://ir.naturessunshine.com/news-events/press-releases/detail/260/natures-sunshine-relaunches-revolutionary-power-line-to)） 最近的发展表明，运营环境更加积极。在2025年末和2026年初，公司报告了强劲的财务业绩，上调了业绩指引，并强调了销售势头和利润趋势的改善。根据其财务沟通，公司还继续回购股票，同时保持稳健的资产负债表状况，包括截至2025年末的现金和零债务。对于投资者而言，NATR 可以被视为一家拥有国际分销、内部制造能力和近期运营复苏的美国天然健康消费品公司，如果执行保持一致，其投资价值可能会提高。（[ir.naturessunshine.com](https://ir.naturessunshine.com/news-events/press-releases/detail/267/natures-sunshine-reports-strong-fourth-quarter-and-full/?utm_source=openai)）
